Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.

被引：0
|
作者：
Naito, Yushi [1 ]
Nagayama, Jun [2 ]
Sano, Yuta [2 ]
Inoue, Satoshi [2 ]
Matsuo, Kazuna [2 ]
Sano, Tomoyasu [3 ]
Ishida, Shohei [2 ]
Matsukawa, Yoshihisa [2 ]
Kato, Masashi [2 ]
Akamatsu, Shusuke [4 ]
机构：
[1] Nagoya Univ Hosp, Dept Urol, Nagoya, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[3] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-180-5577-2829-12292; 283-183-180-5577-5578; 130-540-543-4790; 261-436-2730; 6; 5; 2; 256; 4; 38092-25779; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [41] Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors
    Gebrael, Georges
    Sayegh, Nicolas
    Tripathi, Nishita
    Goel, Divyam
    McFarland, Taylor
    Ebrahimi, Hedyeh
    Nordblad, Blake
    Chigarira, Beverly
    Thomas, Vinay Mathew
    Sahu, Kamal Kant
    Li, Haoran
    Chehrazi-Raffle, Alexander
    Kohli, Manish
    Agarwal, Neeraj
    Swami, Umang
    Maughan, Benjamin L.
    UROLOGY PRACTICE, 2024, 11 (01) : 32 - 35
  • [42] Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer
    Shore, Neal
    Garcia-Horton, Viviana
    Terasawa, Emi
    Ayyagari, Rajeev
    Grossman, Jamie Partridge
    Waldeck, Adrianus Reginald
    FUTURE ONCOLOGY, 2023, 19 (05) : 385 - 395
  • [43] Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy
    Sena, Laura A.
    Wang, Hao
    Lim, Su J.
    Rifkind, Irina
    Ngomba, Nduku
    Isaacs, John T.
    Luo, Jun
    Pratz, Caroline
    Sinibaldi, Victoria
    Carducci, Michael A.
    Paller, Channing J.
    Eisenberger, Mario A.
    Markowski, Mark C.
    Antonarakis, Emmanuel S.
    Denmeade, Samuel R.
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 302 - 309
  • [44] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Todd Yezefski
    Heather H. Cheng
    Elahe Mostaghel
    Michael C. Haffner
    Radhika A. Patel
    Navonil De Sarkar
    Gavin Ha
    Ruth Dumpit
    Brianna Woo
    Aaron Lin
    Patrick Panlasigui
    Nerina McDonald
    Michael Lai
    Katie Nega
    Jeannette Hammond
    Petros Grivas
    Andrew Hsieh
    Bruce Montgomery
    Peter S. Nelson
    Evan Y. Yu
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 194 - 200
  • [45] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Yezefski, Todd
    Cheng, Heather H.
    Mostaghel, Elahe
    Haffner, Michael C.
    Patel, Radhika A.
    De Sarkar, Navonil
    Ha, Gavin
    Dumpit, Ruth
    Woo, Brianna
    Lin, Aaron
    Panlasigui, Patrick
    McDonald, Nerina
    Lai, Michael
    Nega, Katie
    Hammond, Jeannette
    Grivas, Petros
    Hsieh, Andrew
    Montgomery, Bruce
    Nelson, Peter S.
    Yu, Evan Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 194 - 200
  • [46] Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series
    Tran, Elizabeth U.
    Ovruchesky, Eric
    Yamamoto, Kyra
    Marley, Samantha
    Song, Alexander
    Pan, Elizabeth
    Lee, Aaron M.
    Herchenhorn, Daniel
    Denmeade, Sam
    Antonarakis, Emmanuel S.
    Markowski, Mark
    Mckay, Rana R.
    PROSTATE, 2024,
  • [47] Androgen receptor degraders and transactivation domain inhibitors targeting castration-resistant prostate cancer
    Elshan, N. G. Ralalage Dayan
    An, Jiabin
    Jung, Michael
    Rettig, Matthew
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [48] Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer
    Grimm, Marc-Oliver
    Foller, Susan
    Leucht, Katharina
    UROLOGIE, 2023, : 1269 - 1280
  • [49] Androgen receptor (AR) aberrations in castration-resistant prostate cancer
    Waltering, Kati K.
    Urbanucci, Alfonso
    Visakorpi, Tapio
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 360 (1-2) : 38 - 43
  • [50] Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    Feng, Qin
    He, Bin
    FRONTIERS IN ONCOLOGY, 2019, 9
12345